Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

Inappropriate activation of proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK ... with cetuximab and mFOLFOX6 was 2.2% for alkaline phosphatase, 1.3% for ALT, and 0.9% for AST.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Inappropriate activation of proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK ... receiving BRAFTOVI in combination with cetuximab and mFOLFOX6 was 2.2% for alkaline phosphatase, 1.3% for ALT, ...

Constitutive ALK activity in cancers results in the activation of several downstream pathways that are shared with other tyrosine kinases. Many of these pathways have already been characterized.

In this article, we are going to take a look at where Alaska Air Group, Inc. (NYSE:ALK) stands against the other stocks Jim Cramer recently discussed. In his recent appearance on CNBC's Squawk on ...

The Zacks Consensus Estimate for ALK’s fourth-quarter 2024 earnings per share has been revised downward by 26.6% in the past 60 days to 47 cents. However, the consensus mark implies a 56.7% rise ...

With strong historical performance and strategic initiatives, ALK is likely to meet or exceed 2024 Q4 guidance and achieve robust earnings in 2025. Alaska’s third quarter earnings demonstrated a ...